Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
2022 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2022 ; : 961-968, 2022.
Article in English | Scopus | ID: covidwho-2223081

ABSTRACT

Sharing individual-level pandemic data is essential for accelerating the understanding of a disease. For example, COVID-19 data have been widely collected to support public health surveillance and research. In the United States, these data need to be de-identified before being released to the public due to privacy concerns. However, current data publishing approaches for individual-level pandemic data, such as those adopted by the U.S. Centers for Disease Control and Prevention (CDC), have not flexed over time to account for the dynamic nature of infection rates. Thus, the policies generated by these strategies may either raise privacy risks or impair the data utility (or usability). To optimize the tradeoff between privacy risk and data utility, we introduce a game theoretic model that adaptively generates policies to publish individual-level COVID-19 data according to infection dynamics. We model the data publishing process as a two-player Stackelberg game between a data publisher and a data recipient and then search for the best strategy for the publisher. In this game, we consider 1) the average accuracy of predicting future case counts for all demographic groups, and 2) the mutual information between the original data and the released data. We use COVID-19 case data from Vanderbilt University Medical Center from March 2020 to December 2021 to demonstrate our model and evaluate its effectiveness. The experimental results show that our game theoretic model outperforms all baseline approaches, including those adopted by CDC, while maintaining low privacy risk. © 2022 IEEE.

2.
25th IEEE International Conference on Intelligent Transportation Systems, ITSC 2022 ; 2022-October:3429-3434, 2022.
Article in English | Scopus | ID: covidwho-2136420

ABSTRACT

People's travel has changed greatly under the impact of COVID-19. However, it is controversial that whether traffic restrictions of COVID-19 have a positive or negative impact on traffic accidents. At present, there are few studies on the variations of traffic accidents under the impact of COVID-19 in China, and quantitative analysis is rare. Therefore, this study explores the traffic accidents characteristics of W city seriously affected COVID-19. Based on wavelet transform, traffic accident prediction model is established using property damage only accidents data to predict accident frequency without the impact of COVID-19. Compared with the actual traffic accidents frequency, this paper quantitatively analyzes the impact of COVID-19 on traffic accident. The results show that traffic accidents show a trend of decline-bottom-recovery;the frequency of accidents after the recovery is more than the previous year's level;compared with other periods in 2020, the proportion of injury accidents increased sharply during the period when traffic restrictions were gradually loose. The result of accident prediction shows that BP neural network has the best prediction effect. After the implementation of traffic restrictions, the frequency of accidents shows three stages: rapid decline, bottom and continuous rise. In the three stages, the frequency of property damage only accidents decreased by 379.06, 654.72 and 288.19 per day on average. © 2022 IEEE.

3.
International Conference on Privacy in Statistical Databases, PSD 2022 ; 13463 LNCS:361-374, 2022.
Article in English | Scopus | ID: covidwho-2059704

ABSTRACT

The COVID-19 pandemic highlights the need for broad dissemination of case surveillance data. Local and global public health agencies have initiated efforts to do so, but there remains limited data available, due in part to concerns over privacy. As a result, current COVID-19 case surveillance data sharing policies are based on strong adversarial assumptions, such as the expectation that an attacker can readily re-identify individuals based on their distinguishability in a dataset. There are various re-identification risk measures to account for adversarial capabilities;however, the current array insufficiently accounts for real world data challenges - particularly issues of missing records in resources of identifiable records that adversaries may rely upon to execute attacks (e.g., 10 50-year-old male in the de-identified dataset vs. 5 50-year-old male in the identified dataset). In this paper, we introduce several approaches to amend such risk measures and assess re-identification risk in light of how an attacker’s capabilities relate to missing records. We demonstrate the potential for these measures through a record linkage attack using COVID-19 case surveillance data and voter registration records in the state of Florida. Our findings demonstrate that adversarial assumptions, as realized in a risk measure, can dramatically affect re-identification risk estimation. Notably, we show that the re-identification risk is likely to be substantially smaller than the typical risk thresholds, which suggests that more detailed data could be shared publicly than is currently the case. © 2022, Springer Nature Switzerland AG.

4.
Chinese Journal of New Drugs ; 29(15):1734-1737, 2020.
Article in Chinese | Scopus | ID: covidwho-825266

ABSTRACT

Coronavirus disease 2019 (COVID-19) occurred in several countries since the end of 2019. Some infected patients have severe complications, such as acute respiratory distress syndrome and multiple organ dysfunction syndrome. Effective treatment methods are urgently needed. Several clinician groups are attempting to apply stem cells in seriously or critically ill patients with novel coronavirus infected pneumonia. In this paper, we briefly discuss some related issues, such as subject selection, safety and efficacy evaluation, as well as risk management, which should be concerned during the clinical trials based on the defects in clinical trial protocols, and thus provided some advice for investigators. © 2020, Chinese Journal of New Drugs Co. Ltd. All right reserved.

SELECTION OF CITATIONS
SEARCH DETAIL